Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 2, 2009, Pages 398-410

  Molina, Jean Michel ^a   Ait Khaled, Mounir ^b   Rinaldi, Roberto ^c   Penco, Giovanni ^d   Baril, Jean Guy ^e   Cauda, Roberto ^f   Soriano, Vicente ^g   Pialoux, Gilles ^h   Wire, Mary Beth ⁱ   Lou, Yu ⁱ   Givens, Naomi ^b   Craig, Charles ^b   Nichols, Garrett W ^b   Barbosa, Inês ^b   Yeo, Jane ^b   Cooper, David ^j   Clumeck, Nathan ^j   Trottier, Sylvie ^j   Smith, Graham ^j   Logue, Ken ^j   Conway, Brian ^j   Tsoukas, Christos ^j   Partisiani, Maria Louisa ^j   Sereni, Daniel ^j   Lafeuillade, Alain ^j   Bergmann, Jean François ^j   Khuong Josses, Marie Aude ^j   Bouchaud, Olivier ^j   Plettenberg, Andreas ^j   Gargalianos Kakolyris, Panagiotis ^j   Chrysos, George ^j   Sighinolfi, Laura ^j   Mazzotta, Francesco ^j   Filice, Gaetano ^j   Caramello, Pietro ^j   Blanco, Francisco ^j   Domingo, Pere ^j   Estrada, Vicente ^j   Pulido, Federico ^j   Terrón, Jose Alberto ^j   Górgolas, Miguel ^j   Coll, Blai ^j   Portilla, Joaquín ^j   Johnson, Margaret ^j   Huengsberg, Mia ^j   Easterbrook, Phillipa ^j   Winston, Alan ^j   more..

^a SAINT LOUIS HOSPITAL   (France)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Div Malattie Infettive   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e Clinique Medicale du Quartier Latin   (Canada)

^f CATHOLIC UNIVERSITY   (Italy)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HÔPITAL TENON   (France)

ⁱ GLAXOSMITHKLINE   (United States)

^j NONE

more..

Author keywords

Dual boosted PIs; High dose FPV RTV; LPV RTV; Multi PI experienced; Protease inhibitors (PI)

Indexed keywords

AMPRENAVIR PHOSPHATE; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ACUTE KIDNEY FAILURE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTI-HIV AGENTS; CARBAMATES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 67650727422     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp198     Document Type: Article

References (24)

1. Zaccarelli M, Tozzi V, Lorenzi P et al. Does drug class multiresistance affect survival? Analysis from a cohort of HIV patients who experienced treatment failure. In: Abstracts of the XIII International HIV Drug Resistance Workshop 2004; Tenerife. Antiviral Ther 2004; 9: Abstract 139.
2. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet 2000; 355: 1158-59.
3. Hammer S, Vaida F, Kara K et al. for the AIDS Clinical Trials Group 398 Study Team. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. JAMA 2002; 288: 169-80.
4. La Porte CJ, Wasmuth JC, Schneider K et al. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003; 17: 1700-2.
5. Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial (ESS100732). Lancet 2006; 368: 476-82.
6. Gathe J, Ive P, Wood R et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 2004; 18: 1529-37.
7. Shelton MJ, Wire MB, Lou Y et al. Pharmacokinetic and safety evaluation of high-dose combinations of fosamprenavir and ritonavir. Antimicrob Agents Chemother 2006; 50: 928-34.
8. Wire MB, Naderer OJ, Masterman AL et al. The pharmacokinetic (PK) interaction between GW433908 (908) with lopinavir (LPV)/ritonavir (RTV) (APV10011 and APV10012). In: Program and Abstracts 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004; Abstract: L-61.
9. Kashuba AD, Tierney C, Downey GF et al. Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results. AIDS 2005; 19: 145-152.
10. Taburet AM, Raguin G, Le Tiec C et al. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2004; 75: 310-23.
11. Collier AC, Tierney C, Downey GF et al. Randomized study of twice-daily lopinavir/ritonavir (LPT/r) or fosamprenavir (FPV)+ritonavir (FPV+r) versus LPV/r +FPV (with tenofovir DF [TDF] and nucleosides [N(t)RTIs]) as rescue therapy. In: Program and Abstracts 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston Abstract: 577.
12. De Luca A, Baldini F, Cingolani A et al. Deep salvage with amprenavir and lopinavir/ritonavir: Correlation of pharmacokinetics and drug resistance with pharmacodynamics. J Acquir Immune Defic Syndr 2004; 35: 359-66.
13. ANRS HIV-1 genotypic drug resistance interpretation's algorithm. National Agency for AIDS Research, 2004. http://www.hivfrenchresistance.org/2004/tab2.html (15 January 2009, date last accessed).
14. ANRS HIV-1 genotypic drug resistance interpretation's algorithm. National Agency for AIDS Research, 2006. http://www.hivfrenchresistance.org/2006/tab2.html (15 January 2009, date last accessed).
15. Kempf DJ, Isaacson JD, King MS et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75: 7462-9.
16. Division of AIDS Clinical Research Policies and Standard Documents. http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/Safety.htm (15 January 2009, date last accessed).
17. Petersen ML, Wang Y, van der Laan MJ et al. Virologic efficacy of boosted double versus boosted single protease inhibitor therapy. AIDS 2007; 21: 1547-54.
18. Walmsley SL, Katlama C, Lazzarin A et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008; 47: 429-40.
19. Kaletra Product Information. http://www.emea.europe.eu/humandocs/Humans/ EPAR/kaletra/kaletra.htm (15 January 2009, date last accessed).
20. Pham PA, Hendrix CW, Barditch-Crovo P et al. Amprenavir and lopinavir pharmacokinetics following co-administration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. Antiviral Ther 2007; 12: 963-9.
21. Molina JM, Cohen C, Katlama C et al. TMC114-C208 Study Group. TMC114-C215 Study Group. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Synd 2007; 46: 24-31.
22. Clotet B, Bellos N, Molina JM et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369: 1169-78.
23. Grinsztejn B, Nguyen BY, Katlama C et al. Protocol 005 Team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369 1261-9.
24. Nelson M, Fätkenheuer G, Konourina I et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24-week results. In: Program and Abstracts 14th Conference on Retroviruses and Opportunistic Infections; 2007 Feb 25-28; Los Angeles (CA), Abstract: 104aLB.